Quarterly report pursuant to Section 13 or 15(d)

Statement of Operations

v2.4.0.6
Statement of Operations (USD $)
3 Months Ended 132 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Mar. 31, 2012
Revenues:      
Research $ 0 $ 0 $ 0
Expenses:      
General and administrative 728,172 1,109,172 28,075,167
Research and development 1,042,700 2,717,527 32,928,303
Patent fees 102,589 72,514 2,203,594
Depreciation and amortization 10,721 14,127 651,258
Total Expenses 1,884,182 3,913,340 63,858,322
Loss from Operations (1,884,182) (3,913,340) (63,858,322)
Other Income (Expense)      
Realized loss on marketable securities 0 0 (13,301)
Interest income 6,249 42,471 1,427,556
Interest expense 0 0 (301,147)
Other income 0 0 56,047
Unrealized (loss) gain on fair value of warrants (261,861) (467,625) 3,414,244
Unrealized gain on fair value of put feature on common stock 0 0 2,315,539
Financing expense 0 (97,667) (640,023)
Beneficial conversion feature 0 0 (1,625,000)
Total Other Income (Expense) (255,612) (522,821) 4,633,915
Net Loss Before Provision for Income Taxes (2,139,794) (4,436,161) (59,224,407)
Provision for Income Taxes 0 0 0
Net Loss $ (2,139,794) $ (4,436,161) $ (59,224,407)
Net loss per share, basic and diluted $ (0.02) $ (0.05)  
Weighted Average number of shares outstanding, basic and diluted 95,345,656 86,251,682